2022
Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder
D’Souza D, Syed SA, Flynn LT, Safi-Aghdam H, Cozzi NV, Ranganathan M. Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder. Neuropsychopharmacology 2022, 47: 1854-1862. PMID: 35660802, PMCID: PMC9372173, DOI: 10.1038/s41386-022-01344-y.Peer-Reviewed Original ResearchConceptsMajor depressive disorderHealthy controlsAntidepressant effectsDosing sessionsPsychotomimetic effectsDepressive disorderAbuse liabilityTreatment-resistant major depressive disorderDose-related safetyTreatment-resistant individualsMDD participantsPhase 1 studyHAMD-17 scoresTreatment of depressionFurther rigorous trialsMin of injectionExploratory pilot studyPsychedelic drugsAdverse eventsBlood pressureHAMD-17Cardiovascular functionRigorous trialsHealthy volunteersHeart rate
2018
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler EAD, Wallace RM, Sloshower JA, D’Souza D. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9: 177. PMID: 29545753, PMCID: PMC5838010, DOI: 10.3389/fphar.2018.00177.Peer-Reviewed Original ResearchCluster headacheClassic serotonergic psychedelicsPersistent therapeutic effectEffects of psychedelicsPotential long-term effectsPsychedelic drugsSystem involvementHeadache disordersTherapeutic resultsPsychedelic-assisted therapyDrug classesTherapeutic effectLong-term effectsMood disordersTherapeutic benefitMethodologic considerationsNeuropsychiatric disordersNeuroendocrine systemPsychedelic effectsHeadacheBeneficial effectsSerotonergic psychedelicsDisordersDrugsRecent reports